Literature DB >> 9329567

Biliary mucin secreted by cultured human gallbladder epithelial cells carries the epitope of CA 19-9.

C von Ritter1, M I Eder, P Stieber, R Lamerz, D Jüngst, M Strigl, G Meyer, C Reuter, G Paumgartner.   

Abstract

Serum CA 19-9 is increased in patients with different gastrointestinal malignancies. Unfortunately, CA 19-9 is also detected in high concentrations in normal bile causing unspecific serum elevations during inflammatory disease of the biliary tract and cholestasis. In order to identify the source of CA 19-9 in bile, the capacity of cultured human gallbladder epithelial cells (HGBEC) to secrete CA 19-9 was investigated. Cells were harvested from gallbladders removed by cholecystectomy and cultured for up to 14 days in collagen I coated 24-well culture dishes. CA 19-9 was measured in the culture medium by a solid-phase CA 19-9 EIA (Boehringer). In addition, culture medium was separated by Sepharose 4B-Cl, Concanavalin-A (Con-A) and CA 19-9 affinity chromatography. Significant CA 19-9 activity was measured in the culture medium after a 24 hour incubation period. Following separation of the culture medium by Sepharose 4B-Cl and Con-A affinity chromatography, 90% of the CA 19-9 activity was recovered in the exclusion volume (> 2000 kDa) from which 90% were identified as Con-A negative. A close correlation was found between CA 19-9 and concentrations of mucin purified from human gallbladder bile. Furthermore, CA 19-9 affinity chromatography selectively extracted mucins from the culture medium of HGBEC. Finally, addition of the mucin secretagogue bethanechol (6 mM) to the culture medium increased CA 19-9 activity in the medium. In conclusion, normal HGBEC secrete mucins carrying the epitope of CA 19-9. During inflammatory biliary disease unspecific elevation of CA 19-9 in serum may reflect both inflammatory hypersecretion and leakage of biliary mucins into serum.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9329567

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  7 in total

1.  A new cause for CA19.9 elevation: heavy tea consumption.

Authors:  M Howaizi; M Abboura; C Krespine; M-S Sbai-Idrissi; O Marty; M Djabbari-Sobhani
Journal:  Gut       Date:  2003-06       Impact factor: 23.059

2.  Elevated serum level of carbohydrate antigen 19-9 in benign biliary stricture diseases can reduce its value as a tumor marker.

Authors:  Mao-Song Lin; Jun-Xing Huang; Hong Yu
Journal:  Int J Clin Exp Med       Date:  2014-03-15

3.  Clinical experience with primary hepatic epithelioid hemangioendothelioma: retrospective study of 33 patients.

Authors:  Long-Rong Wang; Jia-Min Zhou; Yi-Ming Zhao; Hong-Wei He; Zong-Tao Chai; Miao Wang; Yuan Ji; Yi Chen; Chen Liu; Hui-Chuan Sun; Wei-Zhong Wu; Qing-Hai Ye; Jian Zhou; Jia Fan; Zhao-You Tang; Lu Wang
Journal:  World J Surg       Date:  2012-11       Impact factor: 3.352

4.  Prognosis of resected ampullary adenocarcinoma by preoperative serum CA19-9 levels and platelet-lymphocyte ratio.

Authors:  Richard A Smith; Paula Ghaneh; Robert Sutton; Michael Raraty; Fiona Campbell; John P Neoptolemos
Journal:  J Gastrointest Surg       Date:  2008-06-10       Impact factor: 3.452

5.  Liver Abscess With a Markedly High Level of Carbohydrate Antigen 19-9.

Authors:  Yusuke Yoshino; Kazunori Seo; Ichiro Koga; Naohisa Matsunaga; Takatoshi Kitazawa; Yoriyuki Takamori; Yasuo Ota
Journal:  Gastroenterology Res       Date:  2012-09-20

6.  Hepatocellular carcinoma with hilar bile duct tumor thrombus versus hilar Cholangiocarcinoma on enhanced computed tomography: a diagnostic challenge.

Authors:  Xiaoqi Zhou; Jifei Wang; Mimi Tang; Mengqi Huang; Ling Xu; Zhenpeng Peng; Zi-Ping Li; Shi-Ting Feng
Journal:  BMC Cancer       Date:  2020-01-22       Impact factor: 4.430

7.  Serum cytokine biomarker panels for discriminating pancreatic cancer from benign pancreatic disease.

Authors:  Victoria E Shaw; Brian Lane; Claire Jenkinson; Trevor Cox; William Greenhalf; Christopher M Halloran; Joseph Tang; Robert Sutton; John P Neoptolemos; Eithne Costello
Journal:  Mol Cancer       Date:  2014-05-20       Impact factor: 27.401

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.